Gregory C Knapp1, Olusegun Alatise2, Bolatito Olopade3, Marguerite Samson4, Olalekan Olasehinde2, Funmilola Wuraola2, Oluwole O Odujoko5, Akinwunmi O Komolafe5, Olujide O Arije6, Philip E Castle7, J Joshua Smith1, Martin R Weiser1, T Peter Kingham1. 1. Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America. 2. Department of Surgery, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. 3. Department of Medical Microbiology and Parasitology, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. 4. Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York, United States of America. 5. Department of Morbid Anatomy and Forensic Medicine, College of Health Sciences, Obafemi Awolowo University, Ile-Ife, Nigeria. 6. Institute of Public Health, Obafemi Awolowo University, Ile-Ife, Nigeria. 7. Department of Epidemiology and Public Health, Albert Einstein College of Medicine, Bronx, New York, United States of America.
Abstract
INTRODUCTION: There is a paucity of prospective data on the performance of the fecal immunochemical test (FIT) for colorectal cancer (CRC) screening in sub-Saharan Africa. The aim of this exploratory analysis was to evaluate the feasibility and performance of FIT in Nigeria. METHODS: This was a prospective, single-arm study. A convenience sample of asymptomatic, average-risk individuals between 40-75 years of age were enrolled at Obafemi Awolowo University Teaching Hospital. Study participants returned in 48 hours with a specimen for ova and parasite (O&P) and qualitative FIT (50ug/g) testing. Participants with a positive FIT had follow-up colonoscopy and those with intestinal parasites were provided treatment. RESULTS: Between May-June 2019, 379 individuals enrolled with a median age of 51 years (IQR 46-58). In total, 87.6% (n = 332) returned for FIT testing. FIT positivity was 20.5% (95% CI = 16.3%-25.2%). Sixty-one (89.7%) of participants with a positive FIT had a follow-up colonoscopy (n = 61), of whom 9.8% (95%CI:3.7-20.2%) had an adenoma and 4.9% (95%CI:1.0-13.7%) had advanced adenomas. Presence of intestinal parasites was inversely related to FIT positivity (6.5% with vs. 21.1% without parasites, p = 0.05). Eighty-two percent of participants found the FIT easy to use and 100% would recommend the test to eligible family or friends if available. CONCLUSIONS: Asymptomatic, FIT-based CRC screening was feasible and well tolerated in this exploratory analysis. However, the high FIT positivity and low positive predictive value for advanced neoplasia raises concerns about its practicality and cost effectiveness in a low-resource setting such as Nigeria.
INTRODUCTION: There is a paucity of prospective data on the performance of the fecal immunochemical test (FIT) for colorectal cancer (CRC) screening in sub-Saharan Africa. The aim of this exploratory analysis was to evaluate the feasibility and performance of FIT in Nigeria. METHODS: This was a prospective, single-arm study. A convenience sample of asymptomatic, average-risk individuals between 40-75 years of age were enrolled at Obafemi Awolowo University Teaching Hospital. Study participants returned in 48 hours with a specimen for ova and parasite (O&P) and qualitative FIT (50ug/g) testing. Participants with a positive FIT had follow-up colonoscopy and those with intestinal parasites were provided treatment. RESULTS: Between May-June 2019, 379 individuals enrolled with a median age of 51 years (IQR 46-58). In total, 87.6% (n = 332) returned for FIT testing. FIT positivity was 20.5% (95% CI = 16.3%-25.2%). Sixty-one (89.7%) of participants with a positive FIT had a follow-up colonoscopy (n = 61), of whom 9.8% (95%CI:3.7-20.2%) had an adenoma and 4.9% (95%CI:1.0-13.7%) had advanced adenomas. Presence of intestinal parasites was inversely related to FIT positivity (6.5% with vs. 21.1% without parasites, p = 0.05). Eighty-two percent of participants found the FIT easy to use and 100% would recommend the test to eligible family or friends if available. CONCLUSIONS: Asymptomatic, FIT-based CRC screening was feasible and well tolerated in this exploratory analysis. However, the high FIT positivity and low positive predictive value for advanced neoplasia raises concerns about its practicality and cost effectiveness in a low-resource setting such as Nigeria.
Authors: Douglas J Robertson; Jeffrey K Lee; C Richard Boland; Jason A Dominitz; Francis M Giardiello; David A Johnson; Tonya Kaltenbach; David Lieberman; Theodore R Levin; Douglas K Rex Journal: Gastrointest Endosc Date: 2016-10-18 Impact factor: 9.427
Authors: Enrique Quintero; Marta Carrillo; Antonio Z Gimeno-García; Manuel Hernández-Guerra; David Nicolás-Pérez; Inmaculada Alonso-Abreu; Maria Luisa Díez-Fuentes; Víctor Abraira Journal: Gastroenterology Date: 2014-08-13 Impact factor: 22.682
Authors: Olusegun Isaac Alatise; Omobolaji O Ayandipo; Ademola Adeyeye; Ken Seier; Akinwunmi O Komolafe; Matthew O Bojuwoye; Oludapo O Afuwape; Ann Zauber; Adeleye Omisore; Samuel Olatoke; Adegboyega Akere; Olusola Famurewa; Mithat Gonen; David O Irabor; T Peter Kingham Journal: Cancer Date: 2018-04-12 Impact factor: 6.860
Authors: S J Winawer; A G Zauber; M N Ho; M J O'Brien; L S Gottlieb; S S Sternberg; J D Waye; M Schapiro; J H Bond; J F Panish Journal: N Engl J Med Date: 1993-12-30 Impact factor: 91.245
Authors: L Sharp; L Tilson; S Whyte; A O'Ceilleachair; C Walsh; C Usher; P Tappenden; J Chilcott; A Staines; M Barry; H Comber Journal: Br J Cancer Date: 2012-02-16 Impact factor: 7.640
Authors: Olusegun I Alatise; Anna J Dare; Patrick A Akinyemi; Fatimah B Abdulkareem; Samuel A Olatoke; Gregory C Knapp; T Peter Kingham Journal: Lancet Glob Health Date: 2022-07 Impact factor: 38.927
Authors: Akbar K Waljee; Eileen M Weinheimer-Haus; Amina Abubakar; Anthony K Ngugi; Geoffrey H Siwo; Gifty Kwakye; Amit G Singal; Arvind Rao; Sameer D Saini; Andrew J Read; Jessica A Baker; Ulysses Balis; Christopher K Opio; Ji Zhu; Mansoor N Saleh Journal: Gut Date: 2022-04-13 Impact factor: 31.793